Viking Therapeutics Stock Soars on Positive Obesity Drug Maintenance Data

Viking Therapeutics (NASDAQ: VKTX) shares surged nearly 40% in pre-market trading after the biopharmaceutical company announced positive top-line results from a maintenance study of its experimental obesity drug, VK2735. The data showed that patients could maintain significant weight loss with less frequent dosing, a key development in the highly competitive weight-loss drug market.

Study Shows Strong Weight Loss Maintenance

According to the company's announcement, the 12-week maintenance study of VK2735, a dual agonist of GLP-1 and GIP receptors, yielded compelling results. Key findings include:

• Patients receiving the drug every other week preserved up to 97% of their prior weight loss.
• Monthly dosing maintained up to 90% of prior weight loss.
• Both dosing schedules showed a statistically significant separation from the placebo group, which maintained 61% of prior weight loss.

Viking also highlighted an encouraging safety and tolerability profile, with rates of gastrointestinal-related adverse events observed during the maintenance period being comparable to those seen in the placebo group.

Market Impact and Competitive Edge

Ad

The positive data sent Viking's stock up 39.5% to $42 per share in pre-open trading, as reported by Investing.com. This move was driven entirely by the company's clinical results, as the broader S&P 500 was nearly flat, underscoring the significance of the news for investors.

The results address a critical challenge in the obesity treatment space: the ability to sustain weight loss with a reduced treatment burden. A less frequent, effective maintenance dosing schedule could provide VK2735 with a significant competitive advantage in a market with established players like Eli Lilly. This data provides clinical validation for a differentiation strategy focused on patient adherence and convenience.

Next Steps for Viking

Following these results, Viking plans to explore oral maintenance dosing regimens for VK2735, which would build upon the subcutaneous formulation used in the current study. The company's late-stage development is also advancing, with its Phase 3 VANQUISH trials now fully enrolled.

Viking previously reported a strong cash position of $502 million at the end of the second quarter, which analysts noted provides a solid financial runway to fund its pipeline through these critical clinical milestones.